Literature DB >> 25442933

Improving and accelerating drug development for nervous system disorders.

Diana E Pankevich1, Bruce M Altevogt2, John Dunlop3, Fred H Gage4, Steve E Hyman5.   

Abstract

Advances in the neurosciences have placed the field in the position where it is poised to significantly reduce the burden of nervous system disorders. However, drug discovery, development, and translation for nervous system disorders still pose many unique challenges. The key scientific challenges can be summarized as follows: mechanisms of disease, target identification and validation, predictive models, biomarkers for patient stratification and as endpoints for clinical trials, clear regulatory pathways, reliability and reproducibility of published data, and data sharing and collaboration. To accelerate nervous system drug development, the Institute of Medicine's Forum on Neuroscience and Nervous System Disorders has hosted a series of public workshops that brought together representatives of industry, government (including both research funding and regulatory agencies), academia, and patient groups to discuss these challenges and offer potential strategies to improve the translational neuroscience.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25442933      PMCID: PMC4254615          DOI: 10.1016/j.neuron.2014.10.007

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  25 in total

1.  Novartis to shut brain research facility.

Authors:  Alison Abbott
Journal:  Nature       Date:  2011-12-06       Impact factor: 49.962

2.  Is pharma running out of brainy ideas?

Authors:  Greg Miller
Journal:  Science       Date:  2010-07-30       Impact factor: 47.728

3.  Trial watch: Phase II failures: 2008-2010.

Authors:  John Arrowsmith
Journal:  Nat Rev Drug Discov       Date:  2011-05       Impact factor: 84.694

4.  Too many roads not taken.

Authors:  Aled M Edwards; Ruth Isserlin; Gary D Bader; Stephen V Frye; Timothy M Willson; Frank H Yu
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

5.  Believe it or not: how much can we rely on published data on potential drug targets?

Authors:  Florian Prinz; Thomas Schlange; Khusru Asadullah
Journal:  Nat Rev Drug Discov       Date:  2011-08-31       Impact factor: 84.694

6.  Getting pharmaceutical R&D back on target.

Authors:  Mark E Bunnage
Journal:  Nat Chem Biol       Date:  2011-06       Impact factor: 15.040

Review 7.  Medicines for the mind: policy-based "pull" incentives for creating breakthrough CNS drugs.

Authors:  Dennis W Choi; Robert Armitage; Linda S Brady; Timothy Coetzee; William Fisher; Steven Hyman; Atul Pande; Steven Paul; William Potter; Benjamin Roin; Todd Sherer
Journal:  Neuron       Date:  2014-11-05       Impact factor: 17.173

8.  Next-generation treatments for mental disorders.

Authors:  Thomas R Insel
Journal:  Sci Transl Med       Date:  2012-10-10       Impact factor: 17.956

9.  Revolution stalled.

Authors:  Steven E Hyman
Journal:  Sci Transl Med       Date:  2012-10-10       Impact factor: 17.956

Review 10.  Animal models of pain: progress and challenges.

Authors:  Jeffrey S Mogil
Journal:  Nat Rev Neurosci       Date:  2009-03-04       Impact factor: 34.870

View more
  64 in total

1.  Cross-species translation of the Morris maze for Alzheimer's disease.

Authors:  Katherine L Possin; Pascal E Sanchez; Clifford Anderson-Bergman; Roland Fernandez; Geoffrey A Kerchner; Erica T Johnson; Allyson Davis; Iris Lo; Nicholas T Bott; Thomas Kiely; Michelle C Fenesy; Bruce L Miller; Joel H Kramer; Steven Finkbeiner
Journal:  J Clin Invest       Date:  2016-01-19       Impact factor: 14.808

2.  The NIMH experimental medicine initiative.

Authors:  Thomas R Insel
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

3.  Updating the Research Domain Criteria.

Authors:  Charles A Sanislow
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

4.  Back to basics: luring industry back into neuroscience.

Authors:  Steven E Hyman
Journal:  Nat Neurosci       Date:  2016-10-26       Impact factor: 24.884

Review 5.  Clinical Trials in a Dish: The Potential of Pluripotent Stem Cells to Develop Therapies for Neurodegenerative Diseases.

Authors:  Kelly M Haston; Steven Finkbeiner
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-28       Impact factor: 13.820

Review 6.  Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications.

Authors:  Hsin-Pei Shih; Xiaodan Zhang; Alex M Aronov
Journal:  Nat Rev Drug Discov       Date:  2017-10-27       Impact factor: 84.694

7.  Dispositional negativity, cognition, and anxiety disorders: An integrative translational neuroscience framework.

Authors:  Juyoen Hur; Melissa D Stockbridge; Andrew S Fox; Alexander J Shackman
Journal:  Prog Brain Res       Date:  2019-04-17       Impact factor: 2.453

8.  Functional assessment of glucocerebrosidase modulator efficacy in primary patient-derived macrophages is essential for drug development and patient stratification.

Authors:  Natalie J Welsh; Christina A Gewinner; Kavita Mistry; Mumta Koglin; Juniebel Cooke; Matthew Butler; Ben Powney; Malcolm Roberts; James M Staddon; Anthony H V Schapira
Journal:  Haematologica       Date:  2019-09-26       Impact factor: 9.941

9.  Memantine and Ketamine Differentially Alter NMDA Receptor Desensitization.

Authors:  Nathan G Glasgow; Nadezhda V Povysheva; Andrea M Azofeifa; Jon W Johnson
Journal:  J Neurosci       Date:  2017-09-06       Impact factor: 6.167

10.  Dual functionalized liposome-mediated gene delivery across triple co-culture blood brain barrier model and specific in vivo neuronal transfection.

Authors:  Bruna Dos Santos Rodrigues; Hiroshi Oue; Amrita Banerjee; Takahisa Kanekiyo; Jagdish Singh
Journal:  J Control Release       Date:  2018-07-31       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.